000061947 001__ 61947
000061947 005__ 20240111111735.0
000061947 0247_ $$2doi$$a10.1038/s41598-017-06101-6
000061947 0248_ $$2sideral$$a100713
000061947 037__ $$aART-2017-100713
000061947 041__ $$aeng
000061947 100__ $$aCliment, E.
000061947 245__ $$aEffect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
000061947 260__ $$c2017
000061947 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061947 5203_ $$aPatients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration and the presence of FH-causing mutations on T2DM prevalence in HeFH. Data were collected from the Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion criteria were definite or probable HeFH in patients aged =18 years. T2DM prevalence in HeFH patients was compared with data of the general population. 1732 patients were included. The prevalence of T2DM was lower in patients with HeFH compared with the general population (5.94% vs 9.44%; OR: 0.606, 95% CI 0.486-0.755, p < 0.001). Risk factors for developing T2DM were male sex, age, body mass index, hypertension, baseline triglyceride levels and years on statin therapy. The prevalence of T2DM in HeFH patients was 40% lower than that observed in the general population. Gene mutations and LDL cholesterol concentrations were not risk factors associated with the prevalence of T2DM in patients with HeFH. The prevalence of T2DM in patients with HeFH was 40% lower than in the general population matched for age and sex.
000061947 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000061947 590__ $$a4.122$$b2017
000061947 591__ $$aMULTIDISCIPLINARY SCIENCES$$b12 / 64 = 0.188$$c2017$$dQ1$$eT1
000061947 592__ $$a1.533$$b2017
000061947 593__ $$aMultidisciplinary$$c2017$$dQ1
000061947 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061947 700__ $$0(orcid)0000-0002-1894-1621$$aPérez-Calahorra, S.
000061947 700__ $$aMarco-Benedí, V.
000061947 700__ $$aPlana, N.
000061947 700__ $$aSánchez, R.
000061947 700__ $$aRos, E.
000061947 700__ $$aAscaso, J.F.
000061947 700__ $$aPuzo, J.
000061947 700__ $$aAlmagro, F.
000061947 700__ $$aLahoz, C.
000061947 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000061947 700__ $$aPedro-Botet, J.
000061947 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000061947 773__ $$g7, 1 (2017), [8 pp]$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322
000061947 8564_ $$s1347941$$uhttps://zaguan.unizar.es/record/61947/files/texto_completo.pdf$$yVersión publicada
000061947 8564_ $$s107571$$uhttps://zaguan.unizar.es/record/61947/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061947 909CO $$ooai:zaguan.unizar.es:61947$$particulos$$pdriver
000061947 951__ $$a2024-01-11-10:58:53
000061947 980__ $$aARTICLE